tag pharma-regulation 
World of DTC Marketing
FEBRUARY 19, 2021
When will pharma stop using programmatic online ads? NewsGuard found that 67% of the COVID misinformation sites had Google advertising tags and 30% had tags from The Trade Desk. Again and again, I have seen robust fraud and online ads being placed on sites that pharma would normally block in their system.
Pharmaceutical Technology
DECEMBER 5, 2022
Cannabinoid receptors are a popular therapeutic target for cannabinoid-based drugs in the treatment of pain, neurological disorders and inflammation, according to GlobalData’s Pharma Intelligence Centre Drugs database. This is closely followed by CB2 receptors in second place.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 17, 2020
N o one industry is ever quite like another, but there are some valuable lessons for pharma marketing from examining how the financial sector uses technology, builds brands on social channels and approaches digital content. Nevertheless, the advent of COVID-19 is forcing pharma, and many other sectors, to make some radical changes.
pharmaphorum
SEPTEMBER 15, 2020
Companies like prescription glasses firm Warby Parker, shoe brand Rothy’s and tele-dentistry’s SmileDirectClub have grown up in today’s digitally native environment and can offer some key pointers for pharma. As part of this, a number of big pharma companies are also racing to develop a safe and effective vaccine for the coronavirus.
pharmaphorum
AUGUST 21, 2022
Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. Auvelity is the first drug Axsome has taken through to regulatory approval, but could be the first of a string of new products for the company, according to Tabuteau.
Intouch Solutions
APRIL 11, 2024
In the pharma industry, precision engagement can be used to present patients, healthcare professionals (HCPs), and other stakeholders with relevant information and support at the right time. As AI continues to evolve, its impact on pharma is expected to grow, delivering benefits to patients, healthcare professionals, and companies alike.
pharmaphorum
MAY 17, 2021
Apellis Pharma has secured FDA approval for its complement C3 inhibitor Empaveli as a treatment for paroxysmal nocturnal hemoglobinuria (PNH) – with a label that will allow it to challenge Alexion’s established therapies directly. . billion and $1.1
Expert insights. Personalized for you.
180 
Let's personalize your content